Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Abacavir/lamivudine and emtricitabine/tenofovir DF, each combined with efavirenz or atazanavir + ritonavir, were compared in treatment-naive patients in ACTG 5202
- An interim DSMB review found an excess of virologic failures in the abacavir/lamivudine arm vs the emtricitabine/tenofovir DF arm in patients with baseline HIV-1 RNA ≥ 100,000 copies/mL (14% vs 7%; P = .0003) (Table 5)[Sax 2009]
- In other clinical trials comparing abacavir/lamivudine and emtricitabine/tenofovir DF, varying results were observed regarding their comparative efficacy, depending on the design of the study and the third agent used (Table 6)
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy, Tropism